#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
Statins, Lp(a), and upcoming podcast guests
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.
#18 – Richard Isaacson, M.D.: Alzheimer’s prevention
“Anyone with a brain is at risk for Alzheimer’s.” —Richard Isaacson
#03 – Ron Krauss, M.D.: a deep dive into heart disease
“Anybody interested in this field should probably understand the origins.” —Ron Krauss